Abstract
Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.
| Original language | English |
|---|---|
| Pages (from-to) | 1017-1025 |
| Number of pages | 9 |
| Journal | Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends |
| Volume | 19 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Animals
- Clinical Trials as Topic
- Diabetes Mellitus, Type 2
- Dipeptidyl-Peptidase IV Inhibitors
- Drug Therapy, Combination
- Female
- Humans
- Hypoglycemia
- Hypoglycemic Agents
- Insulin Resistance
- Male
- Pyrazines
- Thiazolidinediones
- Triazoles
Fingerprint
Dive into the research topics of 'Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver